Entinostat: a promising treatment option for patients with advanced breast cancer
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which potently and selectively inhibits class I and IV HDAC enzymes. This action promotes histone hyperacetylation and transcriptional activation of specific genes, with subsequent inhibition of cell proliferation, terminal differentiation and apoptosis. This oral HDAC inhibitor has been evaluated in Phase I and II trials in patients with advanced malignancies, and is in general well tolerated. Entinostat does not currently have regulatory approval for clinical use; however promising preclinical and clinical data exist in hormone-resistant breast cancer. An ECOG-ACRIN Phase III registration study is ongoing in advanced breast cancer (E2112, NCT02115282) and aims to confirm the overall survival advantage observed with the combination of exemestane and entinostat/placebo in the Phase II setting (ENCORE301 trial). This article provides an overview of the chemistry, pharmacokinetics/pharmacodynamics and available clinical data for entinostat with a focus on advanced breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Entinostat, an oral HDAC inhibitor, induces protein lysine acetylation in preclinical models, which leads to downregulation of estrogen-independent growth factor signaling pathways and normalization of estrogen receptor levels.9,10”
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Deacetylase inhibition promotes the generation and function of regulatory T cells
Tao, R., de Zoeten, E. F., Özkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B., Turka, L. A., Olson, E. N., Greene, M. I., et al. (2007) · Nature Medicine · doi:10.1038/nm1652 · Cited by 924
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Self-citationKim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Amir, E., Seruga, B., Niraula, S., Carlsson, L., & Ocaña, A. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr242 · Cited by 622
Witta, S. E., Gemmill, R. M., Hirsch, F. R., Coldren, C. D., Hedman, K., Ravdel, L., Helfrich, B., Dziadziuszko, R., Chan, D. C., Sugita, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1988 · Cited by 515
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 430
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Ryan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 411
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391
Clinical Studies of Histone Deacetylase Inhibitors
Prince, H. M., Bishton, M. J., & Harrison, S. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2785 · Cited by 356
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer.
Belinsky, S. A., Klinge, D. M., Stidley, C. A., Issa, J. J., Herman, J. G., March, T. H., & Baylin, S. B. (2003) · PubMed · Cited by 320
Robertson, J. F. R., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Macpherson, E., Lindemann, J., & Ellis, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1136 · Cited by 310
Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors
Magner, W. J., Kazim, A. L., Stewart, C., Romano, M. A., Catalano, G., Grande, C., Keiser, N., Santaniello, F., & Tomasi, T. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7017 · Cited by 294
Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives
Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., & Nakanishi, O. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980565u · Cited by 293
Fandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S.-H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203547 · Cited by 282
Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., Tidwell, M. L., Greer, J., Chung, E. J., Lee, M.-J., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021873 · Cited by 281
Reddy, P., Maeda, Y., Hotary, K., Liu, C., Reznikov, L. L., Dinarello, C. A., & Ferrara, J. L. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400380101 · Cited by 266
Müller, B. M., Jana, L., Kasajima, A., Lehmann, A., Prinzler, J., Budczies, J., Winzer, K.-J., Dietel, M., Weichert, W., & Denkert, C. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-215 · Cited by 256
Prebet, T., Sun, Z., Figueroa, M. E., Ketterling, R., Melnick, A., Greenberg, P. L., Herman, J., Juckett, M., Wang, E. S., Smith, M. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3102 · Cited by 246
Simonini, M. V., Camargo, L. M., Dong, E., Maloku, E., Veldic, M., Costa, E., & Guidotti, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510341103 · Cited by 229
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis
Krusche, C. A., W�lfing, P., Kersting, C., Vloet, A., B�cker, W., Kiesel, L., Beier, H. M., & Alfer, J. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1668-2 · Cited by 228
Brogdon, J. L., Xu, Y., Szabo, S. J., An, S., Buxton, F., Cohen, D., & Huang, Q. (2007) · Blood · doi:10.1182/blood-2006-04-019711 · Cited by 227
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.
Zhu, W., Lakshmanan, R. R., Beal, M. D., & Otterson, G. A. (2001) · PubMed · Cited by 226
Sharma, D., Saxena, N. K., Davidson, N. E., & Vertino, P. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0402 · Cited by 208
Maeda, T., Towatari, M., Kosugi, H., & Saito, H. (2000) · Blood · doi:10.1182/blood.v96.12.3847 · Cited by 207
Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K. M., Ellis, L., Sotomayor, P., Shrikant, P., Fenstermaker, R., & Pili, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030815 · Cited by 202
Keen, J. C., Lan, Y., Mack, K. M., Pettit, C., Smith, D., Sharma, D., & Davidson, N. E. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1026146524737 · Cited by 175
Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1461 · Cited by 171
Munster, P. N., Marchion, D., Thomas, S., Egorin, M., Minton, S., Springett, G., Lee, J.-H., Simon, G., Chiappori, A., Sullivan, D., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605293 · Cited by 167
Hess‐Stumpp, H., Bracker, T. U., Henderson, D. A., & Politz, O. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.009 · Cited by 165
Connolly, R. M., Li, H., Jankowitz, R. C., Zhang, Z., Rudek, M. A., Jeter, S. C., Slater, S. A., Powers, P., Wolff, A. C., Fetting, J. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1729 · Cited by 162
Self-citationBuglio, D., Georgakis, G. V., Hanabuchi, S., Arima, K., Khaskhely, N. M., Liu, Y.-J., & Younes, A. (2008) · Blood · doi:10.1182/blood-2008-01-133769 · Cited by 161
Sabnis, G. J., Goloubeva, O., Chumsri, S., Nguyen, N., Sukumar, S., & Brodie, A. M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2458 · Cited by 158
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Khan, O., Fotheringham, S., Wood, V., Stimson, L., Zhang, C., Pezzella, F., Duvic, M., Kerr, D. J., & La Thangue, N. B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913912107 · Cited by 152
Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138
Ruscetti, M. A., Dadashian, E. L., Guo, W., Quach, B., Mulholland, D. J., Park, J. W., Tran, L. M., Kobayashi, N., Bianchi-Frias, D., Xing, Y., et al. (2015) · Oncogene · doi:10.1038/onc.2015.444 · Cited by 136
Kummar, S., Gutierrez, M., Gardner, E. R., Donovan, E., Hwang, K., Chung, E. J., Lee, M.-J., Maynard, K., Kalnitskiy, M., Chen, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0791 · Cited by 131
Fan, J., Yin, W.-J., Lu, J.-S., Wang, L., Wu, J., Wu, F.-Y., Di, G.-H., Shen, Z.-Z., & Shao, Z.-M. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0354-x · Cited by 129
HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma
Buglio, D., Khaskhely, N. M., Voo, K. S., Martinez-Valdez, H., Liu, Y.-J., & Younes, A. (2011) · Blood · doi:10.1182/blood-2010-08-303701 · Cited by 117
Epigenetics as a Therapeutic Target in Breast Cancer
Connolly, R., & Stearns, V. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9263-3 · Cited by 117
Self-citationHodges-Gallagher, L., Valentine, C. D., Bader, S. E., & Kushner, P. J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9459-6 · Cited by 110
Entinostat for treatment of solid tumors and hematologic malignancies
Knipstein, J., & Gore, L. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.613822 · Cited by 110
Schech, A. J., Kazi, A. A., Yu, S. L., Shah, P., & Sabnis, G. J. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0778 · Cited by 97
Hooker, J. M., Kim, S. W., Alexoff, D., Xu, Y., Shea, C., Reid, A., Volkow, N., & Fowler, J. S. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn9000268 · Cited by 92
Shah, P., Gau, Y., & Sabnis, G. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2784-7 · Cited by 86
Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Arts, J. J. G., Schepper, S. D., & Emelen, K. V. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456657 · Cited by 83
Zhou, Q. Y., Shaw, P. G., & Davidson, N. E. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0148-5 · Cited by 75
Sabnis, G. J., Goloubeva, O. G., Kazi, A. A., Shah, P., & Brodie, A. H. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0345 · Cited by 74
Tomita, Y., Lee, M.-J., Lee, S., Tomita, S., Chumsri, S., Cruickshank, S., Ordentlich, P., & Trepel, J. B. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1219008 · Cited by 72
Piekarz, R., Sackett, D. L., & Bates, S. E. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e31803c73cc · Cited by 57
Self-citationLee, J., Bartholomeusz, C., Mansour, O. C., Humphries, J., Hortobágyi, G. N., Ordentlich, P., & Ueno, N. T. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3014-7 · Cited by 54
Trichostatin A Inhibits Epithelial Mesenchymal Transition Induced by TGF-β1 in Airway Epithelium
Park, I., Kang, J.-H., Shin, J., & Lee, H.-M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162058 · Cited by 50
2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
Bennet, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70392-8 · Cited by 38
Vendetti, F. P., Topper, M. J., Huang, P., Dobromilskaya, I., Easwaran, H., Wrangle, J. M., Baylin, S. B., Poirier, J. T., & Rudin, C. M. (2014) · Oncotarget · doi:10.18632/oncotarget.2695 · Cited by 36
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor
Acharya, M. R., Sparreboom, A., Sausville, E. A., Conley, B. A., Doroshow, J. H., Venitz, J., & Figg, W. D. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0058-8 · Cited by 36
The biology of hormone refractory breast and prostate cancer: An NCI workshop report
Mohla, S., Stearns, V., Sathyamoorthy, N., Rosenfeld, M. G., & Nelson, P. M. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.21.9918 · Cited by 21
Acharya, M. R., Karp, J. E., Sausville, E. A., Hwang, K., Ryan, Q. C., Gojo, I., Venitz, J., Figg, W. D., & Sparreboom, A. (2006) · Investigational New Drugs · doi:10.1007/s10637-005-5707-6 · Cited by 20
Ihle, M. A., Merkelbach‐Bruse, S., Hartmann, W., Bauer, S., Ratner, N., Sonobe, H., Nishio, J., Larsson, O., Åman, P., Pédeutour, F., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.35 · Cited by 17
Research works printed but not linked: 1
- 10.1016/S1470-2045(14)71159-3 · DOI · Paper page
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
HDAC Inhibitors in Acute Myeloid Leukemia
San José-Enériz, E., Gimenez-Camino, N., Agirre, X., & Prosper, F. (2019) · Cancers · doi:10.3390/cancers11111794 · Cited by 222
“Entinostat (MS-275) is a synthetic benzamide derivative class I HDACi that potently and selectively leads to cell cycle arrest and hyperacetylation of histones H3 and H4 [167,193,194].”
BackgroundMolecular hybridization: a powerful tool for multitarget drug discovery
de Sena Murteira Pinheiro, P., Franco, L. S., Montagnoli, T. L., & Fraga, C. A. M. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2322990 · Cited by 204
The Chemical Biology of Reversible Lysine Post-translational Modifications
Wang, Z. A., & Cole, P. A. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.07.002 · Cited by 201
Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M.-J., Yuno, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3305 · Cited by 133
“HDAC inhibition has been demonstrated preclinically to improve immune competency through increased MHC presentation and tumor antigen expression and reduced number and function of immunosuppressive cells (15, 17 – 21), particularly myeloid-derived suppressor cells (MDSC; refs.21 ,22).”
Metadata
- Authors
- Connolly, R. M., Rudek, M. A., & Piekarz, R.
- Affiliations
- Sidney Kimmel Comprehensive Cancer Center,Johns Hopkins School of Medicine, Baltimore, MD, USA
- Johns Hopkins University (US)
- National Institutes of Health (US)
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2017-03-09
- Volume
- 13
- Issue
- 13
- Pages
- 1137-1148
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- PMC
- PMC5618943
- OpenAlex
- W2591958823
- Cited by
- 148
- References
- 66
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 22 · 2023: 22 · 2022: 16 · 2021: 19 · 2020: 15 · 2019: 14 · 2018: 7 · 2017: 3
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Future Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Celgene
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- entinostat, histone deacetylase inhibitors, advanced breast cancer, hormone-resistant breast cancer, histone hyperacetylation, benzamide derivatives, pharmacokinetics, pharmacodynamics, anticancer drug development
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Female, Humans, Neoplasm Staging, Pyridines, Apoptosis, Epigenesis, Genetic, Cell Line, Tumor, Cell Proliferation, Histone Deacetylase Inhibitors, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.